Head-to-head · Cost-Efficiency Index
Eden vs Hims & Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Eden
People who will trade a higher sticker price for verified nationwide access and stronger clinical oversight.
Visit EdenHims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersThe verdict
Eden takes it, leading the Cost-Efficiency Index 86 to 83. You pay a premium per month, but you buy back certainty: all-50 access and high-disclosure clinical oversight that hold their value. Hims & Hers still earns a B — People who want a familiar, app-driven consumer brand and only need semaglutide.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Eden.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Eden | Hims & Hers |
|---|---|---|
| Cost-Efficiency Index | 86/100 | 83/100 |
| Semaglutide / mo | $239/mo | $199/mo |
| Tirzepatide / mo | $349/mo | Not disclosed |
| Semaglutide / yr (modeled) | $2,868 | $2,388 |
| Tirzepatide / yr (modeled) | $4,188 | — |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #15 | #22 |
Eden
86/100Where the value is
- High transparency — clear supply-chain and clinician disclosure lowers hidden-cost risk
- Nationwide availability with both molecules disclosed
- Strong clinical oversight adds value beyond the raw price
The tradeoffs
- Premium per-month cost drags its normalized value score
- Compounded only — no brand-name access
Regulatory note: the FDA issued a warning letter to Eden Health International Inc. dba Eden in June 2026. We still list and link to Eden; you should know the letter is on the public record before you decide.
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.